Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein delivery from biodegradable microspheres

J L Cleland1

  • 1Genentech, Inc., South San Francisco, California 94080, USA.

Pharmaceutical Biotechnology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A slow release formulation of insulin as a treatment for osteoarthritis.

Osteoarthritis and cartilage·2002
Same author

Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres.

Journal of pharmaceutical sciences·2001
Same author

Comparison of the rates of deamidation, diketopiperazine formation and oxidation in recombinant human vascular endothelial growth factor and model peptides.

AAPS pharmSci·2001
Same author

Comparison between light induced and chemically induced oxidation of rhVEGF.

Pharmaceutical research·2001
Same author

Partial molar volume, surface area, and hydration changes for equilibrium unfolding and formation of aggregation transition state: high-pressure and cosolute studies on recombinant human IFN-gamma.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis.

Journal of controlled release : official journal of the Controlled Release Society·2001
Same journal

Formulation development of protein dosage forms.

Pharmaceutical biotechnology·2002
Same journal

Regulatory considerations in the development of protein pharmaceuticals.

Pharmaceutical biotechnology·2002
Same journal

Quality assurance and quality control for biopharmaceutical products.

Pharmaceutical biotechnology·2002
Same journal

Fundamentals of freeze-drying.

Pharmaceutical biotechnology·2002
Same journal

Membrane filtration.

Pharmaceutical biotechnology·2002
Same journal

Fundamentals of thermal sterilization processes.

Pharmaceutical biotechnology·2002
See all related articles

Developing biodegradable microspheres for protein delivery requires expertise in polymer science and protein stability. Early preclinical studies are crucial for validating controlled-release formulations and optimizing production for therapeutic applications.

Area of Science:

  • Biomaterials Science
  • Pharmaceutical Technology
  • Drug Delivery Systems

Background:

  • Successful biodegradable microsphere formulation for protein delivery hinges on polymer chemistry, engineering, and protein stability.
  • Interdisciplinary investigation is essential before protein encapsulation.
  • Consideration of preclinical studies in animal models is vital for assessing continuous-release dosage form feasibility.

Purpose of the Study:

  • To outline the critical components and considerations for developing biodegradable microsphere formulations for protein delivery.
  • To emphasize the importance of early preclinical validation of controlled-release formulations.
  • To discuss the selection and optimization of polymers and manufacturing processes.

Main Methods:

  • Review of polymer chemistry, focusing on approved polylactides (poly(lactic acid), poly(glycolic acid), poly(lactic-coglycolic) acid).

Related Experiment Videos

  • Description of multiphase processes for microsphere production.
  • Emphasis on process optimization for yield and desired microsphere characteristics (loading, release, size).

    • Main Results:

    • Polylactides are currently the only approved polymers for human use in controlled delivery.
    • Microsphere production involves multi-step processes requiring thorough optimization.
    • Validation of aseptic processes and final product assessment methods are necessary before clinical studies.

    Conclusions:

    • Biodegradable microspheres offer reduced healthcare costs and a competitive market advantage.
    • These formulations are essential for new indications like neurological diseases requiring long-term delivery.
    • Future success depends on industry commitment to advancing microsphere technology for protein and peptide delivery.